Company founded by Shkreli off the hook in $43 million lawsuit: judge

NEW YORK (Reuters) – Vyera Pharmaceuticals, formerly known as Turing Pharmaceuticals, does not have to pay Impax Laboratories Inc $43 million in a dispute stemming from Turing founder Martin Shkreli’s decision to boost by 5,000 percent the price of a drug Turing bought from Impax, a U.S. judge ruled on Friday.


Source: Reuters Health

Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources

(Reuters) – Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.


Source: Reuters Health